Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
Recruiting · NCT06549465 · Registry updated 2026-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) | PSMA PET-Positive Castration-Resistant Prostate Cancer | Recruiting | Phase 2 | 2026-10-02 | NCT06549465 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Convergent Therapeutics | 1 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Duke University Medical Center | Durham | United States | 505 |
| Laura & Isaac Perlmutter Cancer Center | New York | United States | 2 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| New York Presbyterian/Weill Cornell Medical Center | New York | United States | 2 |
| The Cleveland Clinic Foundation | Cleveland | United States | 55 |
| University of California San Diego | San Diego | United States | 22 |
| Washington University in St. Louis | St Louis | United States | 35 |
| X Cancer Omaha / Urology Cancer Center | Omaha | United States | 1 |